Today: 28 June 2026
Browse Category

NYSE:ABBV 13 December 2025 - 30 December 2025

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie closed Friday at $229.98, near its 52-week high, as U.S. markets ended a quiet post-holiday session with major indexes little changed. No major AbbVie corporate news broke in the past two days, but investor analysis and institutional filings kept the stock in focus. Institutions and hedge funds hold about 70% of shares. The next regular trading session is Monday.
27 December 2025
···
AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie shares closed at $229.89 in a shortened Dec. 24 session, near their 52-week high of $244.81. The company reported Q3 2025 net revenues of $15.776 billion, with Skyrizi and Rinvoq sales outpacing declining Humira revenue. Markets reopen Dec. 26 after the Christmas holiday. AbbVie recently announced a dividend increase effective February 2026.
26 December 2025
·
AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie shares closed at $228.79 Tuesday, up 0.4%, and traded near $229.60 after hours. Trading volume was thin ahead of Wednesday’s early market close for Christmas Eve. Investors tracked U.S. drug pricing talks, AbbVie’s pipeline beyond Botox, and a late legal update on Orilissa. AbbVie remains in its 52-week range of $164 to $245.
24 December 2025
··
AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie shares traded near $228.62 Tuesday afternoon, up 0.31%, as investors weighed new pipeline updates and continued debate over U.S. drug pricing. PharmaVoice reported AbbVie is advancing two next-generation neurotoxins, AGN-151607 and TrenibotE, for both aesthetic and therapeutic uses. Nasdaq highlighted strong Skyrizi and Rinvoq sales, projecting over $25 billion combined in 2025.
23 December 2025
·
AbbVie Stock After Hours (ABBV): Shares Dip After the Bell on Dec. 22, 2025 — Key News, Forecasts, and What to Watch Before Tuesday’s Open

AbbVie Stock After Hours (ABBV): Shares Dip After the Bell on Dec. 22, 2025 — Key News, Forecasts, and What to Watch Before Tuesday’s Open

AbbVie shares closed up 0.48% at $227.91 Monday, then slipped to about $226.05 in early after-hours trading. The move followed news that AbbVie remains a holdout on federal drug-pricing deals, with White House meetings expected after the holidays. Trading volume reached about 4.8 million shares. The stock sits below its early-October peak of $244.81.
23 December 2025
··
AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie shares traded at $227.73 midday Monday, near recent highs, as the company remains one of three major drugmakers not signed onto the White House’s new “most-favored-nation” drug-pricing agreements announced December 19. Investors are watching for AbbVie’s next move on the policy front, while its core immunology drugs and dividend growth continue to anchor fundamentals.
22 December 2025
···
AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie closed at $226.82 on Friday, Dec. 19, up 1.8%, with trading volume spiking to 18.6 million shares, well above average. The company remains in talks with the White House as U.S. drug pricing reforms accelerate, including “most-favored-nation” deals and new TrumpRx programs. AbbVie is expected to visit the White House after the holidays for further negotiations.
22 December 2025
···
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie shares closed at $226.82 on Friday, December 19, up 1.8% on heavy volume ahead of a holiday-shortened week. The company was not included in the White House’s December 19 list of drugmakers agreeing to new MFN pricing deals, leaving policy risk unresolved. Investors are watching for further announcements that could affect sentiment and trading.
21 December 2025
··
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie shares closed at $226.82 on Friday, up 1.8%, nearing a 52-week high with a market cap near $400 billion. U.S. drug pricing policy returned to focus after the Trump administration announced agreements with nine drugmakers, excluding AbbVie, which remains in upcoming negotiations. New Medicare pilot programs tied to international price referencing were also announced. Trading volume approached 19 million shares.
21 December 2025
··
AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie shares closed at $226.82 on Dec. 19, up 1.8%, with trading volume spiking after new U.S. drug-pricing policy announcements. Nine major drugmakers signed price-cut deals with the government, but AbbVie was not among them and remains under investor scrutiny. The stock outperformed pharma peers as investors repositioned amid policy uncertainty.
20 December 2025
·
AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie shares closed at $226.82, up 1.80% Friday, then slipped a penny in after-hours trading. Trading volume surged to about 17.4 million shares as investors reacted to White House drug-pricing deals. AbbVie was not among the nine drugmakers that agreed to new pricing terms and remains in talks with the administration, according to Reuters.
20 December 2025
··
AbbVie Stock (ABBV) After Hours Today: What’s Moving the Shares on Dec. 18, 2025 — and What to Watch Before the Market Opens Friday

AbbVie Stock (ABBV) After Hours Today: What’s Moving the Shares on Dec. 18, 2025 — and What to Watch Before the Market Opens Friday

AbbVie shares closed at $222.82, down 0.66% Thursday, then rose 0.31% to $223.51 after hours. Trading followed reports that AbbVie and other drugmakers may announce U.S. agreements Friday to lower certain drug prices under a White House initiative. No new AbbVie earnings were released. The S&P 500 gained 0.79% on the day.
19 December 2025
·
AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie shares fell 2.2% to $222.44 as of 17:54 UTC Tuesday after Bank of America cut its price target to $233 from $248 and kept a Neutral rating. The stock had traded near the top of its 52-week range before the drop. Analysts remain divided, with consensus 12-month targets ranging from $190 to $289. No major company-specific news drove the decline.
16 December 2025
··
AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie shares closed at $223.32 Friday, down 0.3%, with a market cap near $395 billion. HSBC upgraded the stock to Buy with a $265 target, and Morgan Stanley lifted its target to $269, citing strong growth from Skyrizi and Rinvoq offsetting Humira declines. AbbVie raised 2025 adjusted EPS guidance to $10.61–$10.65 and announced a 5.5% dividend increase to $1.73 per share quarterly.
14 December 2025
··
AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025

AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025

AbbVie shares closed Friday at $223.32, down 0.29% as the S&P 500 fell. The stock was flat for the week, trading between $220.23 and $226.12. Volume spiked Wednesday after HSBC upgraded AbbVie to “Buy” and raised its price target to $265, while Morgan Stanley also boosted its target. AbbVie and OSE Immunotherapeutics amended their partnership on ABBV-230, with OSE regaining early-stage rights.
13 December 2025
1 2 3 4 5 6

Stock Market Today

  • Financial Media Stocks Linked to Market-Moving News Flow
    June 28, 2026, 2:53 PM EDT. Financial media companies wield significant influence on market sentiment by rapidly disseminating news. Investors eye firms that collect and distribute this information, as their valuations often hinge on shifts in audience attention and news catalysts. Australian firms HMC Capital (ASX:HMC) and Navigator Global Investments (ASX:NGI) represent notable examples. HMC Capital focuses on real estate, digital infrastructure, and private credit, but remains loss-making and faces execution risks despite optimistic earnings forecasts. Navigator Global Investments offers access to alternative strategies including hedge funds and private equity, driving revenue primarily through its Lighthouse segment. These firms highlight how information flow intersects with investment products, creating both opportunities and risks for market participants.

Latest articles

Opendoor volume surpasses short interest after Russell 3000 addition

Opendoor shares face Russell 3000 test after 4.5x volume spike

28 June 2026
Opendoor Technologies (NASDAQ:OPEN) surged 448% above average trading volume Friday as its Russell 3000 inclusion took effect, with 171.65 million shares traded—exceeding total short interest and equaling 21% of public float—while the stock closed up 1.63% at $4.37; analysts maintain a Hold consensus and see limited rally potential near current prices.
Coeur Mining shares eye index-driven moves after 8.5% weekly slide

Coeur Mining shares eye index-driven moves after 8.5% weekly slide

28 June 2026
Coeur Mining (NYSE:CDE) ended its first week in the S&P MidCap 400 down 8.5% from June 18, despite Friday’s massive $2.7 billion volume—about 16% of its market cap—highlighting investor caution after recent acquisitions and index changes, as the stock lagged silver-miner peers even with a record quarter expected.
Go toTop